A multi-center study on the association between serum magnesium levels and allostatic load in hemodialysis patients

Zhang, Yingxin; Yang, Zhengling; Yang, Huan; Li, Xiuyong; Li, Zhi; Bai, Youwei; Qian, Guangrong; Wu, Han; Ji, Li; Guo, Yuwen; Yang, Shanfei; Chen, Lei; Yang, Jian; Han, Jun; Ma, Shengyin; Yang, Jing; Yu, Linfei; Shui, Runzhi; Jin, Xiping; Wang, Hongyu; Zhang, Fan; Chen, Tianhao; Li, Xinke; Zong, Xiaoying; Liu, Li; Fan, Jihui; Wang, Wei; Zhang, Yong; Shi, Guangcai; Wang, Deguang; Tao, Shuman

doi:10.3389/fphys.2022.963914

Cited by 2 publications

(4 citation statements)

References 53 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ishimura et al [18] ★★★★ ★ ★★★ 7 Markaki et al [19] ★★★ ★ ★★★ 6 Ortega et al [20] ★★★ ★ ★★★ 6 Broek et al [21] ★★★★ ★ ★★★ 7 Laecke et al [22] ★★★★ ★ ★★★ 7 Lacson et al [11] ★★★★ ★ ★★★ 7 Fein et al [23] ★★★★ ★ ★★★ 6 Sakaguchi et al [14] ★★★★ ★ ★★ 6 Li et al [24] ★★★★ ★ ★★★ 7 de Roij van Zuijdewijn et al [25] ★★★ ★ ★★★ 7 Matias et al [26] ★★★★ ★ ★★★ 7 Garagarza et al [27] ★★★ ★ ★★★ 6 Kurita et al [28] ★★★ ★ ★★★ 6 Yang et al [13] ★★★ ★ ★★★ 7 Cai et al [29] ★★★ ★ ★★★ 7 Ago et al [30] ★★★★ ★ ★★ 7 Hughes et al [31] ★★★★ ★ ★★★ 7 Lv et al [34] ★★★ ★ ★★★ 6 Ferrè et al [32] ★★★ ★ ★★★ 7 Schmaderer et al [35] ★★★ ★ ★★★ 7 Sato et al [36] ★★★★ ★ ★★★ 6 Selim et al [33] ★★★★ ★ ★★★ 7 de Francisco et al [37] ★★★ ★ ★★★ 7 Zhang et al [38] ★★★ ★ ★★★ 7 Ye et al [39] ★★★ ★ ★★★ 7 Li et al [40] ★★★★ ★ ★★ 6 Lu et al [41] ★★★ ★ ★★★ 6 Mizuiri et al [42] ★★★ ★ ★★★ 6 Wu et al [43] ★★★★ ★ ★★★ 7 Ogawa et al [44] ★★★ ★ ★★★ 7 Guan et al [45] ★★★ ★ ★★★ 7…”

Section: Study Queue Selection Comparability Results Measurement Leve...mentioning

confidence: 99%

“…de Francisco et al [37] 2017 Spain 2242 68.1 6 mo Retrospective HD All-cause mortality 7 Zhang et al [38] 2017 China 92 73.92 ± 10.73 5 yrs Retrospective HD All-cause mortality 7 Ye et al [39] 2018 China 402 49.3 ± 14.9 49.9 mo Prospective PD All-cause and cardiovascular mortality 7 Li et al [40] 2019 China 446 53.52 ± 15.21 3 yrs Retrospective HD All-cause and cardiovascular mortality 6 Lu et al [41] 2019 China 413 50.4 ± 14.3 12 mo Retrospective HD All-cause and cardiovascular mortality 6 Mizuiri et al [42] 2019 Japan 215 73 3 yrs Retrospective HD All-cause mortality 6 Wu et al [43] 2019 China 169 60.20 ± 15.64 37 mo Prospective HD All-cause and cardiovascular mortality 7 Ogawa et al [44] 2020 Japan 148 56.4 ± 10.5 6 yrs Prospective HD All-cause mortality 7 Guan et al [45] 2020 China 381 56.1 ± 14.2 6.5 yrs Prospective PD All-cause and cardiovascular mortality 7 CKD = chronic kidney disease, HD = hemodialysis, N = number, NOS = Newcastle-Ottawa Scale, PD = peritoneal dialysis.…”

Section: 32mentioning

confidence: 99%

“…Ishimura et al [18] 2007 0.261 (0.143, 0.477) †,x 0.485 (0.241, 0.975) †,x NR 0.983 (0.313, 3.086) †,x Markaki et al [19] 2012 NR 1.16 (0.34, 3.96) * ,x NR NR Ortega et al [20] 2013 1.5 (0.15, 14.7) †,x NR 0.4 (0.08, 2.5) †,x NR Broek et al [21] 2013 NR NR NR 0.64 (0.39, 1.05) †,x Laecke et al [22] 2013 NR 0.93 (0.89, 0.98) †,x NR NR Lacson et al [11] 2014 1.6 (1.3, 1.96) * ,x NR NR NR Fein et al [23] 2014 0.142 (0.0354, 0.2486) †,x 0.984 (0.9684, 0.9999) †,x NR NR Sakaguchi et al [14] 2014 2.04 (1.9, 2.18) * , ‡ 1.18 (1.07, 1.30) * , ‡ NR NR Li et al [24] 2015 1.28 (1.15, 1.42) * ,x 1.17 (1.05, 1.30) * ,x NR NR de Roij van Zuijdewijn et al [25] 2015 0.85 (0.77, 0.94) †,x 0.88 (0.78, 0.99) †,x 0.73 (0.62, 0.85) †,x 0.73 (0.62, 0.85) †,x Matias et al [26] 2015 NR 0.87 (0.68, 0.99) †,x NR 0.82 (0.72, 0.95) †,x Garagarza et al [27] 2015 NR 0.489 (0.36, 0.76) †,x NR NR Kurita et al [28] 2015 NR NR Yang et al [13] 2016 1.28 (1.09, 1.50) * ,x 1.21 (1.09, 1.50) * ,x NR NR Cai et al [29] 2016 0.041 (0.007, 0.223) †,x 0.075 (0.01, 0.552) †,x 0.007 (0.001, 0.081) †,x 0.003 (0, 0.055) †,x Ago et al [30] 2016 NR NR Hughes et al [31] 2016 NR 1.71 (1.27, 2.30) * ,x NR NR Lv et al [34] 2016 NR NR NR 5.617 (1.628, 19.381) †,x Ferrè et al [32] 2017 Schmaderer et al [35] 2017 0.54 (0.20, 1.46) †,x 0.35 (0.13, 0.97) †,x NR NR Sato et al [36] 2017 de Francisco et al [37] 2017 0.69 (0.54, 0.89) †,x 1.28 (0.97, 1.70) †,x NR NR Zhang et al [38] 2017 0.025 (0.001, 0.528) * , ‡ NR NR NR Ye et al [39] 2018 0.85 (0.71, 1.02) †,x 0.83 (0.68, 1.01) †,x 0.85 (0.67, 1.08) †,x 0.82 (0.64, 1.06) †,x Li et al [40] 2019 0.572 (0.338, 0.797) Lu et al [41] 2019 NR 0.017 (0.002, 0.197) †,x NR 0.011 (0.000, 0.269) †,x Mizuiri et al [42] 2019 1.88 (1.13, 3.08) * ,x 1.72 (1.00, 2.91) * ,x NR NR Wu et al [43] 2019 9.544 (5.372, 16.965)…”

Section: All-cause Mortality Cardiovascular Mortality Studymentioning

confidence: 99%

See 2 more Smart Citations

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Liu

Wang²

2021

Medicine

View full text Add to dashboard Cite

Background:Some studies have found that hypomagnesemia is associated with vascular calcification, atherosclerosis, and cardiovascular disease, which may lead to increased mortality in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) who need to maintain hemodialysis (HD). However, the conclusion of these studies remain controversial.Methods:Relevant literature was retrieved from the database of Cochrane library, PubMed, EMBASE, and CNKI until December 2020, without any language restrictions. The data was analyzed using the Stata 12.0 software.Results:A total of 31 studies were included, involving 205436 participants. The results showed that after multivariable adjusted, hypomagnesemia was significant associated with the risk of all-cause mortality in patients with CKD and end-stage renal disease (ESRD) (hazard ratios [HR] 1.955; 95% confidence interval (95% CI) 1.511-2.528; P = .000; hypomagnesemia vs normal magnesium or hypermagnesemia). In contrast, in patients with CKD and ESRD, hypermagnesemia was negatively correlated with all-cause mortality (HR 0.873; 95% CI 0.793-0.960; P = .005) (per unit increase). Moreover, in the adjusted model, it was observed that hypermagnesemia was significantly associated with a reduced risk of cardiovascular death (HR 0.598; 95% CI 0.094-1.102, P = .020). In addition, subgroup analysis found that hypomagnesemia was closely related to the increase of all-cause mortality in HD patients (HR 1.799; 95% CI 1.375-2.354; P = .000) (hypomagnesemia vs normal magnesium or hypermagnesemia).Conclusion:Our results show that hypomagnesemia is significantly associated with cardiovascular and all-cause mortality in maintenance HD patients. Further studies should be conducted to evaluate the benefits of magnesium correction in maintenance dialysis patients with hypomagnesemia.

show abstract

Section: Study Queue Selection Comparability Results Measurement Leve...mentioning

confidence: 99%

Section: 32mentioning

confidence: 99%

Section: All-cause Mortality Cardiovascular Mortality Studymentioning

confidence: 99%

See 1 more Smart Citation

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Liu

Wang²

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…End-stage kidney disease (ESKD), which is the final stage of renal deterioration characterized by a GFR <15 mL/min/1.73m 2 and symptoms of renal failure including uremia, metabolic acidosis, anemia, electrolyte imbalance, and endocrine disorders [ 10 , 11 ]. Hemodialysis is the main modality for ESKD patients in most countries [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Could long-term dialysis vintage and abnormal calcium, phosphorus and iPTH control accelerate aging among the maintenance hemodialysis population?

Zhang,

Yang,

Yang

et al. 2023

Renal Failure

Self Cite

View full text Add to dashboard Cite

Objective Aging is a complex process of physiological dysregulation of the body system and is common in hemodialysis patients. However, limited studies have investigated the links between dialysis vintage, calcium, phosphorus, and iPTH control and aging. The purpose of the current study was to examine these associations. Methods During 2020, a cross-sectional study was conducted in 3025 hemodialysis patients from 27 centers in Anhui Province, China. Biological age was calculated by a formula using chronological age and clinical indicators. The absence of the target range for serum phosphorus (0.87–1.45 mmol/L), corrected calcium (2.1–2.5 mmol/L) and iPTH (130–585 pg/mL) were identified as abnormal calcium, phosphorus, and iPTH control. Results A total of 1131 hemodialysis patients were included, 59.2% of whom were males (669/1131). The mean (standard deviation) of actual age and biological age were 56.07 (12.79) years and 66.94 (25.88), respectively. The median of dialysis vintage was 4.3 years. After adjusting for the confounders, linear regression models showed patients with abnormal calcium, phosphorus, and iPTH control and on hemodialysis for less than 4.3 years ( B = 0.211, p = .002) or on hemodialysis for 4.3 years or more ( B = 0.302, p < .001), patients with normal calcium, phosphorus, and iPTH control and on hemodialysis for 4.3 years or more ( B = 0.087, p = .013) had a higher biological age. Conclusion Our findings support the hypothesis that long-term hemodialysis and abnormal calcium, phosphorus, and iPTH control may accelerate aging in the hemodialysis population. Further studies are warrant to verify the significance of maintaining normal calcium-phosphorus metabolism in aging.

show abstract

A multi-center study on the association between serum magnesium levels and allostatic load in hemodialysis patients

Cited by 2 publications

References 53 publications

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Could long-term dialysis vintage and abnormal calcium, phosphorus and iPTH control accelerate aging among the maintenance hemodialysis population?

Contact Info

Product

Resources

About